Contraception
Volume 81, Issue 2 , Pages 107-111 , February 2010

Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive

Received 24 June 2009 ,Revised 14 July 2009 ,Accepted 20 July 2009.

References 

  1. Bakry S, Merhi ZO, Scalise TJ, Mahmoud MS, Fadiel A, Naftolin F. Depot-medroxyprogesterone acetate: an update. Arch Gynecol Obstet. 2008;278:1–12
  2. Kaunitz AM. Long-acting contraceptive options. Int J Fertil Menopausal Stud. 1996;41:69–76
  3. Fotherby K, Koetsawang S. Metabolism of injectable formulations of contraceptive steroids in obese and thin women. Contraception. 1982;26:51–58
  4. Haider S, Darney PD. Injectable contraception. Clin Obstet Gynecol. 2007;50:898–906
  5. ACOG practice bulletin . No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453–1472
  6. Espey E, Steinhart J, Ogburn T, Qualls C. Depo-Provera associated with weight gain in Navajo women. Contraception. 2000;62:55–58
  7. Pelkman C. Hormones and weight change. J Reprod Med. 2002;47:791–794
  8. Bahamondes L, Del Castillo S, Tabares G, Arce XE, Perrotti M, Petta C. Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. Contraception. 2001;64:223–225
  9. Taneepanichskul S, Reinprayoon D, Khaosaad P. Comparative study of weight change between long-term DMPA and IUD acceptors — a clinical evaluation. Contraception. 1998;58:149–151
  10. Clark MK, Dillon JS, Sowers M, Nichols S. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Int J Obes. 2005;29:1252–1258
  11. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2002;15:79–82
  12. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med. 2006;160:40–45
  13. World Health Organization, Medical eligibility criteria for contraceptive use. Update 2008, 4th ed. Available at: http://www.who.int/reproductive-health/publications/mec/mec_update_2008.pdf
  14. Armitage P, Berry G. Statistical methods in medical research. 2nd ed.. Oxford: Blackwell Scientific Publications; 1985;
  15. Hair JF, Anderson RE, Tatham RL, Black WC. Multivariate data analysis. 5th ed.. Saddle River, NJ: Prentice-Hall; 1998;
  16. Said S, Omar K, Koetsawang S, et al. A multicentred phase III comparative trial of depo-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg. 1. Contraceptive efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1986;34:223–235
  17. Fraser IS, Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust. 1981;1(1 Suppl):3–9
  18. Amatayakul K, Sivasomboon B, Thanangkul O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception. 1980;22:605–622
  19. Westhoff C, Jain JK, Milsom I, Ray A. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception. 2007;75:261–267
  20. Hassan DF, Petta CA, Aldrighi JM, Bahamondes L, Perrotti M. Weight variation in a cohort of women using copper IUD for contraception. Contraception. 2003;68:27–30
  21. Blanco-Molina A, Trujillo-Santos J, Tirado R, Cañas I, Riera A, Valdés M, et al. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost. 2009;101:478–482

PII: S0010-7824(09)00353-9

doi: 10.1016/j.contraception.2009.07.008

Contraception
Volume 81, Issue 2 , Pages 107-111 , February 2010

Article Tools

* Image Usage & Resolution